The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Https://www.dailymail.co.uk/money/investing/article-12896235/MIDAS-SPECIAL-Follow-tips-Merry-Christmas-picked-formula-success.html
Got a Mention in the Mail today
Eden Research is another innovative UK firm whose shares have motored in recent months, rising 60 per cent to 5.85p since Midas recommended them this summer.
The performance reflects a step-change in this business, which makes pesticides that help crops to grow without harming the environment.
This market is expected to be worth almost £8 billion by 2025, amid increasing concern about the impact of chemical insecticides on consumer health.
Eden works with some of the giants in the industry and only last week announced new approvals for a seed protection product developed with Corteva, one of the largest agricultural firms in the world.
More good news is expected in 2024 and Eden shares should respond.
Traded on: AIMTicker: EDEN Contact: edenresearch.com or 01285 359555
Https://www.virtualinvestorconferences.com/welcome
https://onlinexperiences.com/scripts/Server.nxp
Had to sign up to listen.
Nothing new, but I think it was a presentation in/for the USA.
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
OTC Markets
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading over 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our three public markets: OTCQX® Best Market, OTCQB® Venture Market and Pink® Open Market.
Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.
OTC Link ATS, OTC Link ECN and OTC Link NQB are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.
To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.
https://www.londonstockexchange.com/stock/EDEN/eden-research-plc/company-page
Price at mom 4.40-4.70p
market cap £24.27mio
Depends how it was negotiated. If they where offered £1700 or 170,000 and took the shares , having done their own research on Cobra. That would say they like Cobra as a company/miner/digging for gold/REE.
Most likely it was £1000 or 170, 000. However much diluted shareholders are , they took the shares in payment .
I would take that as a positive view.......
So hopefully see them going up in price... One day !!!
G_G_G Hope you don't mind , just copied your last set of notes on to http://www.michaelwalters.c*m
All the best
I own a fair few of these . not quite as much as you thou .....
Good luck
Hope you are right... I have a few of these . Unfortunately unlikely this weekend. The last RNS from the directors
6 October 2023
ValiRx PLC ("ValiRx" or the "Company")
Statement re Share Price Movement
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, notes the recent increase in the Company's share price and confirms that it is not in possession of unpublished price sensitive information.
The Company notes the announcement published by EUDA Health Holdings Limited in relation to its proposed merger with TheoremRx Inc. The announcement can be viewed in full at the link below:
https://www.globenewswire.com/news-release/2023/10/05/2755433/0/en/EUDA-Health-Holdings-Limited-Enters-into-Letter-of-Intent-for-Proposed-Merger-with-TheoremRx-Inc.html
As initially announced on 2 November 2021, VAL201, the Company's clinical asset for prostate cancer, remains subject to the Letter of Intent with TheoremRx Inc.
The Directors of the Company take responsibility for this announcement.
May get repeated.....
https://www.londonstockexchange.com/news-article/VAL/statement-re-share-price-movement/16156795
Best of Luck all round
I think they will get there one day along with
PYC
Check out Laura's thoughts
https://www.lse.co.uk/ShareChat.html?ShareTicker=PYC&share=physiomics
Tree Shakes – if you hold shares in a company and the price starts to drift downwards, you need to check two things. Firstly check the date and make sure it is not ex-dividend day – your share price will drop by the same amount as the dividend, and this is fine.
WHEN IS that going to effect VALirx..... ???
please put comments that are interesting, re VALIRX......
OMO
Https://www.physiomics.co.uk/meet-our-new-chief-operating-officer-dr-pete-sargent/
Interesting read :-
Pete joins us with experience working for a wide variety of life sciences businesses across R&D and commercial operations, read on to find out why he is excited to join Physiomics and where he sees the most potential!
Q: What attracted you to the role at Physiomics?
: “Having worked across the biopharma industry for many years, I’m acutely aware of the mounting pressures drug development companies are under. Both regulatory and market pressures are pushing these companies to adopt innovative solutions to accelerate and de-risk their R&D, whilst reducing costs. I feel that the solutions Physiomics offer through their proprietary technologies and mathematical modelling expertise makes the company well positioned to support this endeavour. It is this exciting opportunity to contribute to a more efficient and successful drug development process and the business’s potential for growth that attracted me to the role.”
Q: What do you see as Physiomics’ greatest strengths?
A: “A unique ability to listen and work collaboratively with our clients, leveraging deep technical and scientific expertise to deliver tailored solutions to their needs. The broad experience of the team allows us to help clients gain insight into not only their asset, but also how it compares to similar ones in development or on the market. These insights are often very powerful, allowing for informed and more precise decisions to be made across the R&D continuum.”
Q: What opportunities do you see for the company?
A: “I think Physiomics certainly has an exciting future. The business has invested significantly in developing expertise and IP around its core modelling offering, with very positive client feedback and a high percentage of repeat business. With these solid foundations now built, I see an opportunity not only to scale the core business, but to build adjacent offerings in areas such as biostatistics and expand into new indications. Additionally, with continued development of our personalised medicine tools there is also the potential to significantly improve the health outcomes of cancer patients prescribed already marketed medicines.”
Q: What are you most excited about in your new role?
A: “I’ve only been here a couple of weeks, but one thing that immediately struck me is the very high calibre of the team we have here, both in the form of their expertise, technical ability, but also the culture. This, along with the opportunity I see we as a business have in the market, is a powerful combo – this is what excites me!”
PYC linked with OBD?
This from Laura2022 on LSE
https://www.lse.co.uk/ShareChat.html?ShareTicker=PYC&share=physiomics
OBD PYC prostate tests26 Sep 2023 18:22
This was from OBD today
Noticed the precision medicine yet again at the forefront
UK immediate access
The PSE test will be immediately available to men in the UK using the US testing facility to process results initially. OBD is in the process of obtaining ISO15189 certification for a clinical lab within its Oxford, UK laboratory. Once certified, expected early in 2024, PRECISION MEDICINE TESTS( my capitals fyi), like EpiSwitch PSE, will be run there - shortening the overall turnaround time for results.
More information may be found at www.94percent.com. Please contact Oxford BioDynamics client services anytime by emailing the team at pse.test@myobdx.com.
"There is a clear need in everyday clinical practice for a much more accurate blood test that can screen men for prostate cancer and accurately identify those at risk, while sparing those who up to now would be subject to unnecessary, expensive, and invasive procedures. It feels wholly appropriate that the early launch of the test coincides with Prostate Cancer Awareness month," said Dr Jon Burrows, OBD's Chief Executive Officer. "With the news today of the launch of another EpiSwitch-based product, we are continuing to improve patient health whilst also reducing the cost of care."
OBD cruising higher, may go even higher today??
https://www.londonstockexchange.com/stock/OBD/oxford-biodynamics-plc/company-page
closed at 26.80p + 156.46% (16.35)
I have read most of her posts on LSE , she comes across as some one who knows her stuff.
PYC may get a boost in price on the "bacK" of OBD
TEll a few of your mates......
They can help some , not all thou ......But def worth a check.
https://www.physiomics.co.uk/personalised-cancer-treatment/
https://www.physiomics.co.uk/contact/
Https://www.investormeetcompany.com/ Google Investor meet company , if link does not work
just reg , then ask for Light Science meeting .
maybe interesting
closed at 3.30p last night
https://www.londonstockexchange.com/stock/LST/light-science-technologies-holdings-plc/company-page
research-tree report
cobra has reported upgrades to both the gold and rare earth element (ree) mineral resource estimates (mre) at its wudinna multi-mineral project located in south australia’s gawler craton. cobra moves another step closer to demonstrating the commercial opportunity of this unique multi-mineral occurrence in a tier 1 jurisdiction.
i do not pay for research=tree so not read the rest of this report......
https://*********************/companies/uk/banks/cobra-resources-plc/research/shard-capital/double-win-gold-and-rare-earth-resources-both-upgraded/9bc07ec4-de07-44a8-a455-481a7ab98fd0
https://www.londonstockexchange.com/stock/cobr/cobra-resources-plc/company-page
Https://www.physiomics.co.uk/modelling-and-simulation-solutions/
No real idea , if this goes up more or back down.
However having looked at their website ,https://www.physiomics.co.uk/personalised-cancer-treatment/ something I did not know about.
I have put a couple of "golfing" buddies, onto this they are waiting for replies, from Physiomics .....
https://www.physiomics.co.uk/contact/
Price at close 2.20-2.30
https://www.londonstockexchange.com/stock/PYC/physiomics-plc/company-page
Https://www.lse.co.uk/ShareShortPositions.html?shareprice=OCDO&share=Ocado
Still 4.07% held as Shorts..... Always a care needed.... IMO.
Fund % Short Change Date Changed
Aqr Capital Management, Llc 0.50% 0.00% 23 Aug 2023
Arrowstreet Capital, Limited Partnership 0.52% 0.00% 11 Aug 2023
Blackrock Investment Management (Uk) Limited 1.11% 0.00% 1 Aug 2023
Kintbury Capital Llp 0.63% -0.16% 27 Jul 2023
D1 Capital Partners Lp 1.31% 0.10% 18 Jul 2023
Total 4.07%
Good Luck
Https://shorttracker.co.uk/company/GB00B125SX82/
Only 1 shorter ( over 0.5%) .... They may be buying back today!!!
The Mangrove Partners Master Fund, Ltd. 0.59% -0.11% 17 Aug 2023
Https://stockanalysis.com/stocks/ctva/market-cap/
Market cap of Corteva $35 bio , if /if ever they want all Eden's patent's , they will buy Eden .
With their loose change....( They already have 10% & kept and that level after Fundraise)